Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01376323 · ClinicalTrials.gov registry record · Phase 2
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 15
- Study locations
NCT01376323 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 92 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 4 states.
The verdict
NCT01376323, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 15
- Study locations
Study Summary
The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK256073 1mg
- DRUG GSK256073 5mg
- DRUG GSK256073 10mg
- DRUG GSK256073 25mg
Study Locations (15)
Other
- GSK Investigational Site - Nantes
- GSK Investigational Site - Pierre-Bénite
- GSK Investigational Site - Rennes
- GSK Investigational Site - Rueil-Malmaison
- GSK Investigational Site - Alicante
- GSK Investigational Site - Badalona
- GSK Investigational Site - Granada
- GSK Investigational Site - Madrid
- GSK Investigational Site - Cambridge
- GSK Investigational Site - Coventry
- GSK Investigational Site - Newcastle upon Tyne
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miramar
Alabama
- GSK Investigational Site - Anniston
Midlothian
- GSK Investigational Site - Edinburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2011-07-13 |
| Est. Completion | 2012-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01376323
The ClinicalTrials.gov registry entry for NCT01376323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01376323 reports 15 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01376323 about?
NCT01376323 is a clinical study titled "A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin". The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.
What is the current status of trial NCT01376323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2011-07-13. Estimated completion is 2012-09-17.
What conditions does trial NCT01376323 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01376323?
The interventions under investigation include: Placebo (DRUG), GSK256073 1mg (DRUG), GSK256073 5mg (DRUG), GSK256073 10mg (DRUG), GSK256073 25mg (DRUG).
Who is sponsoring clinical trial NCT01376323?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01376323 being conducted?
This trial has 15 study locations across Alabama, Florida, Midlothian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.